Table 1.

Sensitivity to microtubule-interfering drugs in cell lines

Cells	BRCA1 status	IC50	Drug [exposure time] & assay used
Comparison across breast cancer cell lines
HCC1937	ERneg, one deleted allele and one C- terminally truncated allele.	>2μM	Paclitaxel [48h] & MTT (Tassone et al. 2003; Ref. 45)
MCF-7	ERpos, hemizygous for wild type BRCA1	0.1–0.2 μM
MDA-MB231	Homozygous for wt BRCA1	10–20 nM
Comparison across isogenic breast cancer cell lines
HCCBR116	HCC1937 transfected with wt BRCA1	7.73 nM	Paclitaxel [72h] & MTT (Gilmore et al. 2004; ref. 43).
HCCEV1	HCC1937 transfected with empty vector	6.21 μM
MBR62-bcl2	MCF-7 derivative stably transfected with tet-inducible wt BRCA1 (induced)	7.7 nM	Paclitaxel [72h] & cell counting (Quinn et al. 2003; ref. 42).
MBR62-bcl2	MCF-7 derivative stably transfected with tet-inducible wt BRCA1 (non-induced)	96.4 pM
T47D	T47D (BRCA1+/+ and ERpos) transfected with a control siRNA	2.2 μM	Paclitaxel [72h] & cell counting (Quinn et al. 2003; ref. 42).
T47D	T47D transfected with a BRCA1 siRNA	>0.1 mM
HCCBR116	HCC1937 transfected with wt BRCA1	7.7 nM	Paclitaxel [72h] & cell counting (Quinn et al. 2003; ref. 42).
HCCEV1	HCC1937 transfected with empty vector	6.2 μM
HCCBR116		1.9 nM	Vinorelbine [72h] & cell counting (Quinn et al. 2003; ref. 42).
HCCEV1		17 μM
HCCBR18	HCC1937 transfected with wt BRCA1	0.3 nM	Paclitaxel [72h] & cell counting (Quinn et al. 2003; ref. 42).
HCCEV2	HCC1937 transfected with empty vector	1.6 μM
HCCBR mix	HCC1937 transfected with wt BRCA1	1.5 nM	Paclitaxel [72h] & cell counting (Quinn et al. 2003; ref. 42).
HCCEV3	HCC1937 transfected with empty vector	10.7 μM
MCF-7	MCF-7 transfected with a control siRNA	36 nM*	Paclitaxel [72h] & WST-1 cleavage (Chabalier et al. 2006; ref. 46). *IC25 shown.
MCF-7	MCF-7 transfected with a BRCA1 siRNA	4.1 nM*